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Despite the well established ivermectin activity against microﬁlaria, the success of human ﬁlariasis
control programmes requires the use of a macroﬁlaricide compound. Different in vivo trials suggest that
ﬂubendazole (FLBZ), an anthelmintic benzimidazole compound, is a highly efﬁcacious and potent
macroﬁlaricide. However, since serious injection site reactions were reported in humans after the sub-
cutaneous FLBZ administration, the search for alternative pharmaceutical strategies to improve the
systemic availability of FLBZ has acquired special relevance both in human and veterinary medicine. The
goal of the current experimental work was to compare the pharmacokinetic plasma behavior of FLBZ,
and its metabolites, formulated as either an aqueous hydroxypropyl- b -cyclodextrin-solution (HPBCD),
an aqueous carboxymethyl cellulose-suspension (CMC) or a Tween 80-based formulation, in pigs. Ani-
mals were allocated into three groups and treated (2 mg/kg) with FLBZ formulated as either a HPBCD-
solution (oral), CMC-suspension (oral) or Tween 80-based formulation (subcutaneous). Only trace
amounts of FLBZ parent drug and its reduced metabolite were measured after administration of the
different FLBZ formulations in pigs. The hydrolyzed FLBZ (H-FLBZ) metabolite was the main analyte
recovered in the bloodstream in pigs treated with the three experimental FLBZ formulations. The oral
administration of the HPBCD-solution accounted for signiﬁcantly higher (P < 0.05) Cmax and AUC
(23.1 ± 4.4 mg h/mL) values for the main metabolite (H-FLBZ), compared with those observed for the oral
CMC-suspension (AUC ¼ 3.5 ± 1.0 mg h/mL) and injectable Tween 80-based formulation (AUC:
7.5 ± 1.7 mg h/mL). The oral administration of the HPBCD-solution signiﬁcantly improved the poor ab-
sorption pattern (indirectly assessed as the H-FLBZ plasma concentrations) observed after the oral
administration of the FLBZ-CMC suspension or the subcutaneous injection of the Tween 80 FLBZ
formulation to pigs. Overall, the work reported here indicates that FLBZ pharmacokinetic behavior can be
markedly changed by the pharmaceutical formulation.
© 2015 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The control and eventual elimination of neglected tropical dis-
eases (NTD) requires the expansion of interventions such as mass
drug administration (MDA), vector control, diagnostic testing and
effective treatment. Current efforts in this area of tropical public
health have been aimed at onchocerciasis and lymphatic ﬁlariasis
(LF) as well as loiasis as co-infectionwith this other ﬁlaria can causeallos).
Ltd on behalf of Australian Society fsevere adverse reaction in MDA areas. These diseases continue to
cause widespread sickness and disability in many parts of the
world. Of the total population requiring preventive chemotherapy
for LF, 57% live in the South-East Asia Region and 38% live in the
African Region. Onchocerciasis is endemic in 31 countries in Africa
and 6 countries in Latin America, with 99% of cases of
onchocerciasis-related blindness found in Africa (WHO, 2013).
Chemotherapy remains the main approach to treatment, con-
trol, and elimination of ﬁlarial infections aided where suitable by
adjunct activities such as vector control and enhanced program
management. Current onchocerciasis therapy employ ivermectinor Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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production of mf by female worms (Basa~nez et al., 2008). These
effects reduce the pathology of the disease and prevent trans-
mission by blocking repopulation of the skinwithmf for >6months
following a single dose. However, due to the long life-span of the
adult parasites, eradication of the disease will almost certainly
require a ﬁeld-compatiblemacroﬁlaricide. Existingmacroﬁlaricides
have either unacceptable toxicity (e.g., suramin) (Awadzi, 2003) or
induce severe adverse reactions contraindicating their use at doses
required to be effective (e.g., diethylcarbamazine (DEC) (Bird et al.,
1979). For LF, DEC or IVM in combination with albendazole (ABZ)
are used as the basis for the global programme for elimination, but
the availability of a single-dose macroﬁlaricide would provide
chemotherapeutic options that could signiﬁcantly reduce program
duration (Taylor et al., 2010).
Although IVM has had an enormous impact on onchocerciasis
and LF, this agent lacks the ability to kill the adult parasites. Since
the adult worms can survive for many years, it has been necessary
for control programs to continue drug distribution for more than a
decade, for instance, until the adult worms eventually die
(Mackenzie and Geary, 2011). As a consequence, the search for a
macroﬁlaricide that can enhance elimination of ﬁlarial infections,
and the diseases they cause, is a current and relevant goal. Different
in vivo trials suggest that ﬂubendazole (FLBZ), a benzimidazole
methylcarbamate anthelmintic currently licensed for use in
humans for treatment of infection by intestinal nematodes (EMEA,
1997), is a highly efﬁcacious and potent macroﬁlaricide in experi-
mental animals when given parenterally (Zahner and Schares,
1993; Mackenzie and Geary, 2011), including in the feline Brugia
pahangi model, a host in which this parasite occurs naturally. In
addition, FLBZ has been reported to be able to eliminate adult
Diroﬁlaria immitis from dogs after a single injection (Mackenzie and
Geary, 2011). It is important to stress that FLBZ is macroﬁlaricidal in
these models only when given parenterally (as a consequence of its
very low oral bioavailability in standard formulations). Studies in
humans infected with Onchocerca volvulus reported problems
associated with reactions at the intramuscular injection site where
FLBZ, in its oil-based carrier, was administered.
As a chemical class, the benzimidazole methylcarbamates have
very limitedwater solubility, which allows their preparation only as
tablets/suspensions for oral administration in humans. Small dif-
ferences in drug solubility may have a major inﬂuence on their
absorption and resultant pharmacokinetic behavior (Lanusse et al.,
1995). It has been reported that the use of complexing agents such
as hydroxypropyl-b-cyclodextrins (HPBCD) increases the water
solubility of FLBZ and ABZ (Ceballos et al., 2012) and their systemic
drug exposure in different species (Evrard et al., 2002; Ceballos
et al., 2009, 2014). Similar ﬁndings have been reported in humans
(Rigter et al., 2004).
Prospects for an accelerated path to the elimination of oncho-
cerciasis and LF would be much enhanced if a safe and effective
macroﬁlaricide was available (Geary et al., 2010; Mackenzie and
Geary, 2011). Bioavailability is a key pharmacokinetic parameter,
deﬁned as the proportion of a drug administered by a nonvascular
route that gains access to the systemic circulation (Toutain and
Bousquet-Melou, 2004). Bioavailability quantiﬁes the proportion
of a drug which is available to produce systemic effects. When
pharmacological research cannot be done on humans for practical
and ethical reasons, animal models constitute an acceptable alter-
native approach to understand the parasite-drug-host relationship.
In this context, the search for alternative pharmaceutical stra-
tegies to improve FLBZ oral bioavailability may be considered
critical to optimize its pharmacological activity. The goal of the
current experimental work was to compare the pharmacokinetic
behavior of FLBZ, and its metabolites, formulated as either anaqueous hydroxypropyl- b -cyclodextrin-solution, an aqueous car-
boxymethyl cellulose-suspension or a Tween 80-based formula-
tion, in pigs.
2. Materials and methods
2.1. Chemicals
Pure reference standards of FLBZ, reduced-FLBZ (R-FLBZ) and
hydrolyzed-FLBZ (H-FLBZ) used to develop the analytical method-
ology were kindly provided by Janssen Animal Health (Beerse,
Belgium). Oxibendazole (OBZ), used as internal standard, was ob-
tained from Schering Plough (Kenilworth, NJ, USA). HPLC grade
acetonitrile and methanol were from Sintorgan S.A. (Buenos Aires,
Argentina) and J.T. Baker (Phillipsburg, New Jersey, USA), respec-
tively. HPBCDswere from ISP Pharmaceuticals (Cavasol, New Jersey,
USA). Low viscosity grade sodium CMCwas purchased from Anedra
(Buenos Aires, Argentina). Tween® 80 was purchased from Biopack
(Buenos Aires, Argentina).
2.2. Preparation of FLBZ formulations
The FLBZ HPBCD-based solution was prepared by dissolving
FLBZ (0.1%) and HPBCD (10%) in deionized water. The pH of the
formulation was adjusted to 1.2 using HCl (25 mM). The formula-
tion was shaken until total dissolution of the drug and then was
ﬁltrated through a 0.45 mm ﬁlter (Whatman, NJ, USA). The ﬁnal
FLBZ concentration was conﬁrmed by HPLC. The Tween 80-based
formulation was prepared by dissolving FLBZ (0.25%) in Tween
80. The FLBZ-suspension was prepared by addition of FLBZ (0.1%)
and CMC (0.1%) in deionized water (pH ¼ 6.0) with shaking for 6 h.
The FLBZ-CMC suspension was vigorously shaken immediately
before administration to pigs. FLBZ formulations were freshly
prepared and maintained under refrigeration (3e5 C).
2.3. Experimental animals
Sixteen (16) healthy pigs (45.2 ± 7.54 kg) were used in two
different experiments. Pigs were fed ad libitum with a commercial
balanced food and had free access towater. Animals were housed in
pens with concrete ﬂoors, protected from rain and prevailing
winds, but without temperature control. Animal procedures and
management protocols were approved by the Ethics Committee
according to the Animal Welfare Policy (act 087/02) of the Faculty
of Veterinary Medicine, Universidad Nacional del Centro de la
Provincia de Buenos Aires (UNCPBA), Tandil, Argentina (http://
www.vet.unicen.edu.ar).
2.4. Experimental design
Two different experiments were undertaken to generate the
data reported in this article. Experiment 1 was a crossover study
involving two experimental phases. In phase I, pigs received the
following treatments: FLBZ-HPBCD solution (Cavasol®, n ¼ 4, oral
treatment) and FLBZ-CMC suspension (n ¼ 4, oral treatment). After
a 21-day washout period, drug treatments were reversed for each
drug (phase II). Additionally in experiment 2, eight pigs were dosed
subcutaneously with the FLBZ-Tween 80 solution. All treatments
were given as a single dose of 2 mg/kg. Blood samples (5 mL) were
taken from all pigs by anterior vena cava venipuncture into hepa-
rinized Vacutainers® tubes (Becton Dickinson, Franklin Lakes, NJ,
USA), prior to treatment and at 1, 2, 3, 6, 9, 12, 15, 24, 30, 34, 48 and
54 h post-treatment for oral treated groups (experiment 1) and up
to 72 h post-treatment for subcutaneous administration (experi-
ment 2). Plasma was separated by centrifugation at 2000  g for
L. Ceballos et al. / International Journal for Parasitology: Drugs and Drug Resistance 5 (2015) 178e18418015 min. Plasma samples were placed into plastic vials and stored
at 20 C until analyzed by HPLC.
2.5. Analysis of FLBZ and its metabolites
Chromatography was performed on a Shimadzu HPLC platform
(Shimadzu Corporation, Kyoto, Japan), with two LC-10AS solvent
pumps, an automatic sample injector (SIL-10A) with a 50 mL loop,
an ultravioletevisible spectrophotometric detector (UV) (SPD-10A)
reading at 292 nm, a column oven (Eppendorf TC-45, Eppendorf,
Madison, WI, USA) set at 30 C, and a CBM-10A integrator. Data and
chromatograms were collected and analyzed using the Class LC10
software (SPD-10A, Shimadzu Corporation, Kyoto, Japan). The C18
reversed-phase column (5 mm, 250 mm  4.6 mm) was Kromasil
(Kromasil®, Sweden). Elution from the stationary phase was carried
out at a ﬂow rate of 1.2 mL/min using an acetonitrile (34%)/
ammonium acetate buffer (0.025M, pH 5.3, 66%) as a mobile phase.
Plasma samples (500 mL) were spiked with OBZ (20 mL) as in-
ternal standard. FLBZ and its metabolites were extracted using
disposable cartridges (Strata®, Phenomenex, CA, USA) previously
conditioned with 0.5 mL of methanol, followed by 0.5 mL of water,
as described (Moreno et al., 2004). All samples were injected into
cartridges and then sequentially washed with 1.5 mL of water and
eluted with 2 mL of methanol. Identiﬁcation of FLBZ and its me-
tabolites was undertaken by comparison with retention times of
pure reference standards. Complete validation of the analytical
procedures for extraction and quantiﬁcation of drug and metabo-
lites in plasma was performed before starting the analysis of
experimental samples. Retention times for H-FLBZ, R-FLBZ and
FLBZ were 5.7, 7.1 and 14.4 min, respectively. Calibration curves for
each analyte, constructed by least squares linear regression anal-
ysis, showed good linearity, with correlation coefﬁcients 0.998.
The limit of quantiﬁcation (FLBZ and metabolites), deﬁned as the
lowest measured concentration with a CV <20%, accuracy of ±20%
and absolute recovery  70%, was 0.01 mg/mL.
2.6. Pharmacokinetic analysis of the data
Non-compartmental pharmacokinetic analysis for the plasma
concentration versus time curves for H-FLBZ for each individual
animal after FLBZ treatment was conducted using PK Solution 2.0
(Summit research services, CO, USA). The low concentrations of
FLBZ and R-FLBZ quantiﬁed during a short time period precluded
the development of a complete pharmacokinetic analysis of the
data obtained for these molecules after the oral or subcutaneous
administration of FLBZ. The peak concentration (Cmax) and time to
peak concentration (Tmax) for each individual animal were read
from the plotted concentrationetime curve for each analyte. The
elimination half-life (T½el) and absorption (T½ab) or metabolite
formation (T½for) half-lives were calculated as ln2/b and ln 2/k,
respectively. The area under the concentrationetime curve from
0 to the limit of quantiﬁcation (AUC0-LOQ) for FLBZ and metabolites
was calculated by the trapezoidal rule (Gibaldi and Perrier, 1982).
2.7. Statistical analysis
Pharmacokinetic parameters are reported as arithmetic
mean ± SD. The mean pharmacokinetic parameters obtained for
each experimental group in experiment 1 were compared by paired
t-test. Additionally, pharmacokinetic parameters obtained from
experimental groups involved in experiment 1 and 2 were
compared by analysis of variance (ANOVA). A parametric
(ANOVA þ Tukey) and non-parametric (ManneWhitney) were
used where signiﬁcantly differences among standard deviations
were observed. Mean values were considered signiﬁcantly differentat P < 0.05. The statistical analysis was performed using Instat 3.0
Software (Graph Pad Software, CA, USA).
3. Results
During treatment and follow up, pigs from treated groups were
apparently normal without adverse events such as diminished
food/water consumption, ataxia, etc. A local tissue reaction at the
administration site was observed after subcutaneous administra-
tion of FLBZ formulated in Tween 80. This reaction was character-
ized by swelling, discoloration (which was more evident at 7 days
post-injection) and slight alopecia. Fig. 1 shows the mean (±SD)
plasma concentration proﬁles for FLBZ and its metabolites after oral
or subcutaneous administration of the three FLBZ formulations.
The only FLBZ metabolite recovered from plasma samples after
oral administration of the FLBZ-CMC suspension was H-FLBZ,
whichwas quantiﬁed in plasma between 1 and 48 h post-treatment
(Fig. 1b). For these reasons, comparison of relative availability
among the different FLBZ formulations was based on the plasma
levels of H-FLBZ, the main analyte found in the bloodstream of
FLBZ-treated pigs. Fig. 1 d shows the comparative (mean ± SD)
plasma concentration proﬁles of H-FLBZ obtained after oral
administration of FLBZ formulated as an HPBCD-, a conventional
CMC-suspension or a Tween 80-based formulation to healthy pigs.
Table 1 summarizes the main pharmacokinetic parameters
(mean ± SD) for H-FLBZ obtained after oral or subcutaneous
administration of FLBZ as different formulations. H-FLBZ was
detected at 1 h post-treatment (ﬁrst sampling point), and rapidly
increased to reach a Cmax of 1.01 ± 0.1 mg/mL (FLBZ-HPBCD),
0.2 ± 0.1 mg/mL (FLBZ-CMC) and 0.3 ± 0.1 mg/mL (FLBZ-Tween 80) at
a Tmax ranging 9.7e10.5 h post-treatment (Table 1). Cmax values
for H-FLBZ were signiﬁcantly (P < 0.05) higher in pigs treated with
the FLBZ-HPBCD formulation (Table 1) thanwith the CMC or Tween
80 formulations. Additionally, H-FLBZ systemic exposure
(expressed as AUC0-LOQ) was signiﬁcantly higher (P < 0.05) in the
FLBZ-HPBCD group (23.1 ± 4.4 mg h/mL) compared to the oral CMC-
suspension (3.5 ± 1.0 mg h/mL) or the injectable Tween 80-based
formulation (7.5 ± 1.7 mg h/mL) groups. This represents an incre-
ment in the AUC0-LOQ value of 560% (compared to the CMC-based
formulation) and 208% (compared to the Tween 80-based formu-
lation) in the pigs treatedwith FLBZ-HPBCD. After parenteral (FLBZ-
Tween 80) or oral (FLBZ-CMC) administration of FLBZ, a similar
Cmax value for H-FLBZ was observed. However, since this metab-
olite was detected longer after the parenteral treatment, a higher
(P < 0.05) AUC0-LOQ value was obtained in this experimental group
compared to the group treated with the CMC-based suspension
(Table 1). There were no major differences (P > 0.05) in other
pharmacokinetic parameters obtained for H-FLBZ such as Tmax,
T½for and T½el among formulations. The FLBZ-CMC formulation
showed the lowest relative availability. Neither the parent drug nor
the R-FLBZ metabolite could be quantiﬁed in any plasma sample
belonging to this group, since all concentrations were below the
limit of quantiﬁcation (0.01 mg/mL).
Trace amounts of FLBZ and R-FLBZ were measured in plasma
after oral administration of FLBZ as an HPBCD formulation reaching
maximum concentrations of 0.06 ± 0.05 mg/mL and 0.04 ± 0.03 mg/
mL for parent drug and active metabolite, respectively (Fig. 1a).
Additionally, after subcutaneous administration as a Tween 80-
based formulation, low FLBZ plasma concentrations were
measured up to 15 h post-treatment with a Cmax value of
0.06 ± 0.03 mg/mL (Fig. 1c). It is important to highlight that the
plasma concentrations for FLBZ and R-FLBZ (Fig. 1a and c) represent
the mean values obtained from all experimental animals in each
group. In both groups (HPBCD and Tween 80), most of the indi-
vidual concentrations were below the LOQ. Consequently, the low
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Fig. 1. a) b) and c) Plasma concentration proﬁles (mean ± SD) of ﬂubendazole (FLBZ) and its metabolites hydrolyzed-FLBZ (H-FLBZ) and reduced-FLBZ (R-FLBZ) after administration
of FLBZ (2 mg/kg) formulated as either a) hydroxypropyl-b-cyclodextrin (FLBZ-HPBCD)-based solution (oral), b) a conventional carboxymethyl-cellulose suspension (FLBZ-CMC)
(oral) or c) a Tween 80-based formulation (FLBZ-Tween 80) (subcutaneous) to healthy pigs. FLBZ parent drug was not detected after administration of the suspension, d)
Comparative plasma concentrations (mean ± SD) of the hydrolyzed-ﬂubendazole (H-FLBZ) metabolite (main analyte recovered in the bloodstream) obtained after administration of
the three different formulations.
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cluded any individual pharmacokinetic analysis. The basic phar-
macokinetic data obtained for FLBZ are shown in Table 2.Table 1
Pharmacokinetic parameters (mean ± SD) for the hydrolyzed ﬂubendazole (H-FLBZ)
metabolite obtained after the oral administration of ﬂubendazole (FLBZ, 2 mg/kg)
formulated as either a hydroxypropyl-b-cyclodextrin solution (HPBCD), a carbox-
ymethyl cellulosa-suspension (CMC), or a tween 80-based formulation (Tween 80)
to healthy pigs.
Pharmacokinetic parameters H-Flubendazole
HPBCD CMC Tween 80
Cmax (mg/mL) 1.01 ± 0.1a 0.2 ± 0.1b* 0.32 ± 0.1b
Tmax (h) 9.7 ± 5.1a 10.5 ± 1.7a 10.5 ± 2.5a
AUC0-LOQ (mg.h/mL) 23.1 ± 4.4a 3.5 ± 1.0b* 7.5 ± 1.7c
T½for (h) 2.3 ± 1.3a 4.9 ± 1.6a 3.2 ± 1.2a
T½el (h) 9.81 ± 1.9a 13.2 ± 7.6a 11.3 ± 2.3a
Cmax: peak plasma concentration; Tmax: time to the Cmax; AUC0eLOQ: area under
the plasma concentration vs. time curve from 0 to the limit of quantiﬁcation; T½ for:
metabolite formation half life; T½el: elimination half-life.* Indicates statistically
signiﬁcant differences (P<0.05) between FLBZ-HPBCD and FLBZ-CMC groups (paired t
test). Different superscripts indicate statistically signiﬁcant differences (P<0.05) among
experimental groups.4. Discussion
Pigs, dogs, and monkeys are the most common non-rodent
species used in toxicity testing of drugs (Dalgaard, 2015). The cur-
rent report gives an overview of the metabolism and disposition of
FLBZ/metabolites in treated pigs to approximate what might be
expected in humans. FLBZ is a highly efﬁcacious macroﬁlaricide in a
variety of experimental animals, and is a potent and efﬁcacious
anthelmintic for gastrointestinal nematode infections in pigs,
poultry and domestic animals (Mackenzie and Geary, 2011).
Knowledge of anthelmintic drug concentrations (active molecules)
achieved in tissues/ﬂuids at the parasites locationwill contribute to
the understanding of the pharmacokinetics-efﬁcacy relationship.
Plasma concentration proﬁles reﬂect those attained for the
different ﬂuid/tissues where target parasite may be located.
Consequently, this characterization contributes to understanding
the relationship between drug concentration and clinical efﬁcacy,
which is useful to optimize parasite control. Usually, the higher the
concentration achieved in the tissue/ﬂuid where the parasite is
located, the higher the amount of drug reaching the parasite. This is
strongly supported by the ﬁndings from in vivo studies (Hennessy
et al., 1995; Alvarez et al., 2000; Lloberas et al., 2012).
Lipophilic benzimidazole anthelmintics such as FLBZ require
Table 2
Pharmacokinetic parameters (mean ± SD) for ﬂubendazole (FLBZ) obtained after the
oral administration of ﬂubendazole (FLBZ, 2 mg/kg) formulated as either a
hydroxypropyl-b-cyclodextrin solution (HPBCD) or a tween 80-based formulation
(Tween 80) to healthy pigs.
Pharmacokinetic parameters Flubendazole
HPBCD Tween 80
Cmax (mg/mL) 0.06 ± 0.05 0.06 ± 0.03
Tmax (h) 6.00 ± 3.00 3.14 ± 1.35
AUC0-LOQ (mg.h/mL) 0.40 ± 0.26 0.39 ± 0.20
Cmax: peak plasma concentration; Tmax: time to the Cmax; AUC0eLOQ: area under
the plasma concentration vs. time curve from 0 to the limit of quantiﬁcation. FLBZ
was not quantiﬁed after its administration as a carboxymethyl cellulosa-suspension.
P > 0.05.
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larity for excretion. Carbonyl reductases (CBRs) are primarily
involved in FLBZ biotransformation. The main FLBZ metabolic
pathways include reduction of the ketone group to form R-FLBZ,
and hydrolysis of the methylcarbamate group to form H-FLBZ. The
contribution of each metabolite to the total amount of drug
recovered from plasma after FLBZ treatment may differ according
to the animal species considered (Mate et al., 2008). Available data
appear to indicate that, while H-FLBZ has no anthelmintic activity,
R-FLBZ is an active metabolite. The in vitro protoscolicidal (Ceballos
et al., 2011) and in vivo nematocidal (Urbizu et al., 2012) effects of R-
FLBZ have been described. Additionally, its effect on Fasciola
hepatica egg hatching was reported (Alvarez et al., 2009). While R-
FLBZ is themain FLBZmetabolite found in plasma of sheep (Moreno
et al., 2004) and mice (Ceballos et al., 2009), H-FLBZ is the
metabolite which predominates in the systemic circulation of pigs
after FLBZ treatment (Fig. 2), which may represent a disadvantageFig. 2. Main FLBZ metabolic pathways in pigs. These include reduction of the ketone group t
form hydrolyzed ﬂubendazole (H-FLBZ).in this animal species in terms of the ﬁnal anthelmintic activity of
FLBZ against systemically located target parasites.
We found in the present work that the hydrolyzed metabolite
was the main molecule recovered from pigs treated with FLBZ,
representing 97% of the total drug detected in plasma (Fig. 2). Only
trace of FLBZ parent drug and R-FLBZ could be quantiﬁed up to 12 h
(FLBZ) and 15 h (R-FLBZ) post-treatment (HPBCD-based formula-
tion). In agreement with these results, in vitro studies performed in
our laboratory revealed that the rate of production of H-FLBZ by
liver microsomal fractions obtained from pigs was 6.93-fold higher
than R-FLBZ production (Mate et al. unpublished observations).
Furthermore, a different plasma proﬁle was observed in rats, since
similar amounts of FLBZ and H-FLBZ were present in the blood-
stream, with only trace amounts of R-FLBZ (Ceballos et al., 2014).
Although oral bioavailability of FLBZ has been estimated in humans
(EMEA, 1997), no data are available on the plasma pharmacokinetic
pattern of FLBZ and metabolites. However, in vitro studies carried
out in our laboratory have shown that human liver microsomes
produced similar amounts of each metabolite, with the ratio H-
FLBZ/R-FLBZ ¼ 1.30 (Mate et al. unpublished observations). These
results may indicate that the FLBZ metabolic proﬁle in humans
differs from that in pigs and is insteadmore similar to themetabolic
proﬁle observed in mice (Ceballos et al., 2014). The potential in vivo
metabolism of FLBZ to R-FLBZ in humans may be important in
terms of anthelmintic activity, since as previously mentioned, this
metabolite is anthelmintically active.
Clearly, the poor oral absorption of FLBZ after administration in
conventional suspension/tablet formulations is a serious disad-
vantage for the treatment of systemic infections such as ﬁlariases.
Strategies to attain satisfactory oral bioavailability through new
formulations of FLBZ should be evaluated. Enhanced aqueous sol-
ubility and bioavailability of guest molecules is a common effecto form reduced ﬂubendazole (R-FLBZ) and hydrolysis of the methylcarbamate group to
L. Ceballos et al. / International Journal for Parasitology: Drugs and Drug Resistance 5 (2015) 178e184 183observed after drug formulation with cyclodextrins (CDs) (Loftsson
and Duchene, 2007). We have previously reported that incorpora-
tion of FLBZ into an HPBCD formulation signiﬁcantly increased its
water solubility (Ceballos et al., 2012) and systemic exposure in
mice by more than 25-fold compared to the conventional FLBZ
suspension (Ceballos et al., 2009). The relative bioavailability of
albendazole sulphoxide (ABZSO) in mice was also increased by
formulation with CDs (Garcia et al., 2003). Similar ﬁndings have
been reported in humans (Rigter et al., 2004). Since the parent BZD
compounds are not detected or are detected in very low concen-
trations in plasma, the relative availability of benzimidazole
methylcarbamate anthelmintics are commonly assessed trough the
analysis of the plasma concentration proﬁles of their metabolites
(Evrard et al., 2002; Ceballos et al., 2009; Suarez et al., 2011).
Thereby, increased parent drug absorption is related to higher
metabolite plasma exposure. In the present work, the use of an
HPBCD-based formulation of FLBZ orally administered to pigs
induced drastic changes in the H-FLBZ plasma availability, resulting
in signiﬁcantly higher plasma Cmax and AUC values compared to
those obtained after dosing with the FLBZ suspension or the FLBZ
Tween 80-based formulation subcutaneously administered
(Fig. 1d) (P < 0.05).
Local injection site adverse effects were observed in animals
after subcutaneous treatment, which could be related to a reaction
to the solvent used in the formulation (Tween 80), post-injection
drug precipitation and/or the relatively high volume injected
(30 mL approx.). Irritation and post-injection precipitation are
concerns in parenteral drug delivery for poorly water soluble drugs
(Muller et al., 2004). Post-injection drug precipitation may cause
problems in several ways: (1) mechanical irritation caused by
particles of the precipitated drug; (2) irritation to tissues at the
injection site due to the prolonged drug-tissue contact time; and
(3) the possibility of poor and less reproducible systemic bioavail-
ability (Wu et al., 2010). That is in concordance with a low relative
plasma availability achieved for H-FLBZ after Tween 80 subcu-
taneous administrations to pigs. Equivalent FLBZ plasma concen-
tration proﬁles were observed after the HPBCD and the Tween 80
formulation. Since in pigs the main active molecule after FLBZ
treatment is the parent drug (H-FLBZ is an inactive metabolite), a
similar anthelmintic efﬁcacy against systemic parasites could be
expected after the use of HPBCD and the Tween 80 formulation.
However, if in humans a portion of FLBZ can be reduced to R-FLBZ, a
high macroﬁlaricidal efﬁcacy could be expected after the HPBCD
oral administration. This hypothesis needs to be explored.
Overall, the work reported here demonstrates that FLBZ phar-
macokinetic behavior can be markedly altered by changes in
formulation. The cyclodextrin-based formulation improved the
absorption of FLBZ compared to the conventional CMC suspension,
and reached similar FLBZ plasma concentrations than that observed
after the subcutaneous administration of the Tween 80-based
formulation. If an equivalent (similar) pharmacokinetic behavior
can be achieved in humans, it is highly likely that a macroﬁlaricidal
efﬁcacy could be obtained after FLBZ oral administration as a
HPBCD-based formulation. However, this formulation faces two
main impediments: a) the high cost of the HPBCD excipient and b)
the large volume required for potential treatment of humans. Thus,
a crucial next step in the development of FLBZ as a macroﬁlaricide
may be the reduction of costs associated with CD or alternatively,
the selection of a low cost excipient contributing the same beneﬁts
as CDs, enabling an increase in the FLBZ concentration in the oral
pharmaceutical preparation.
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